Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
15c83d26-f9ba-44cc-a920-6941781cdd8b | Neutropenia 4/69 (5.80%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac arrest 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac failure congestive 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac tamponade 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Pericardial effusion 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Abdominal pain 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Ascites 2/69 (2.90%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Colitis 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Gastritis 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Gastritis erosive 1/69 (1.45%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Total: 12/65 (18.46%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Anaemia 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Febrile neutropenia 1/65 (1.54%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Neutropenia 1/65 (1.54%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac arrest 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac failure congestive 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Cardiac tamponade 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Pericardial effusion 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Abdominal pain 2/65 (3.08%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Ascites 2/65 (3.08%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Colitis 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Gastritis 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
15c83d26-f9ba-44cc-a920-6941781cdd8b | Gastritis erosive 0/65 (0.00%) Neutropenia affected the majority of patients in cohort 1 of the primary trial. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Duration of Moderate Neurtopenia Post First Chemotherapy Administration secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Time frame: The first of 4, 21 Day Chemotherapy Cycles secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 80 g/kg/Dose of F-627(TC) secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy. secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: F-627: subcutaneous injection given 1 per chemotherapy. secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Overall Number of Participants Analyzed: 35 secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Mean (Standard Deviation) secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Overall Number of Participants Analyzed: 109 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Measure Type: Number the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Unit of Measure: days 0.6 (1.26) secondary trial: Unit of Measure: participants 0 the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 240 g/kg/Dose of F-627 (TC) secondary trial: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 240 g/kg/Dose of F-627 (TC) secondary trial: [Not Specified] the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 240 g/kg/Dose of F-627 (TC) secondary trial: Time frame: 6 months the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 240 g/kg/Dose of F-627 (TC) secondary trial: Arm/Group Title: AC/PTL the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |
e100212f-5bef-4f84-a3c1-d18a6b3e8355 | primary trial: Arm/Group Title: 240 g/kg/Dose of F-627 (TC) secondary trial: Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months. the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | 0 |